<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540487</url>
  </required_header>
  <id_info>
    <org_study_id>1288.5</org_study_id>
    <nct_id>NCT01540487</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin</brief_title>
  <official_title>Characterisation of Fixed Dose Combination Tablets of Linagliptin 2.5 mg/Metformin 850 mg or Linagliptin 2.5 mg/Metformin 500 mg and Relative Oral Bioavailability Compared With Single Linagliptin 2.5 mg and Metformin 850 mg or 500 mg Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open Label, Randomised, Single-dose, Two-way Crossover, Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the trial is to assess the relative bioavailability of fixed dose combination
      tablets of linagliptin and metformin compared to the administration of two single tablets
      (linagliptin and metformin ) in Chinese subjects. The availability of a fixed dose
      combination tablet is expected to significantly enhance patients` compliance with
      antidiabetic treatment., in particular with concern to the frequent polypharmacy in diabetic
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)</measure>
    <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Measured Concentration (Cmax) of Linagliptin.</measure>
    <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval 0 to the Last Quantifiable Concentration (AUC0-tz)</measure>
    <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Measured Concentration (Cmax) of Metformin</measure>
    <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) for Linagliptin</measure>
    <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
    <description>AUC0-infinity is based on predicted last concentration values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-infinity) for Metformin</measure>
    <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
    <description>AUC0-infinity is based on predicted last concentration values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz for Linagliptin</measure>
    <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>linagliptin/metformin(high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>linagliptin/metformin(low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin/metformin(high dose)</intervention_name>
    <description>patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.</description>
    <arm_group_label>linagliptin/metformin(high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin/metformin(low dose)</intervention_name>
    <description>patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.</description>
    <arm_group_label>linagliptin/metformin(low dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male and female subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1288.5.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <results_first_submitted>June 6, 2013</results_first_submitted>
  <results_first_submitted_qc>June 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2013</results_first_posted>
  <last_update_submitted>June 6, 2013</last_update_submitted>
  <last_update_submitted_qc>June 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lina 2.5mg, Metformin 850mg</title>
          <description>All patients receiving Linagliptin 2.5mg and Metformin 850mg.</description>
        </group>
        <group group_id="P2">
          <title>Lina 2.5mg, Metformin 500mg</title>
          <description>All patients receiving Linagliptin 2.5mg and Metformin 500mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lina 2.5mg, Metformin 850mg</title>
          <description>All patients receiving Linagliptin 2.5mg and Metformin 850mg.</description>
        </group>
        <group group_id="B2">
          <title>Lina 2.5mg, Metformin 500mg</title>
          <description>All patients receiving Linagliptin 2.5mg and Metformin 500mg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="4.4"/>
                    <measurement group_id="B2" value="28.6" spread="4.8"/>
                    <measurement group_id="B3" value="28.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)</title>
        <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
        <population>Treated Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as single tablets.</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as single tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)</title>
          <population>Treated Set.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248" spread="14.5"/>
                    <measurement group_id="O2" value="251" spread="15.3"/>
                    <measurement group_id="O3" value="266" spread="22.1"/>
                    <measurement group_id="O4" value="264" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>99.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.7</ci_lower_limit>
            <ci_upper_limit>104.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>100.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.1</ci_lower_limit>
            <ci_upper_limit>106.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration (Cmax) of Linagliptin.</title>
        <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
        <population>Treated Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as single tablets.</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as single tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration (Cmax) of Linagliptin.</title>
          <population>Treated Set.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.90" spread="23.1"/>
                    <measurement group_id="O2" value="6.81" spread="18.2"/>
                    <measurement group_id="O3" value="7.54" spread="35.4"/>
                    <measurement group_id="O4" value="6.77" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>101.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.4</ci_lower_limit>
            <ci_upper_limit>109.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>111.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.4</ci_lower_limit>
            <ci_upper_limit>123.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval 0 to the Last Quantifiable Concentration (AUC0-tz)</title>
        <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as single tablets.</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as single tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval 0 to the Last Quantifiable Concentration (AUC0-tz)</title>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11700" spread="27.9"/>
                    <measurement group_id="O2" value="12100" spread="23.2"/>
                    <measurement group_id="O3" value="8240" spread="20.8"/>
                    <measurement group_id="O4" value="8010" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>97.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.6</ci_lower_limit>
            <ci_upper_limit>103.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusteg gMean ratio</param_type>
            <param_value>103.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.2</ci_lower_limit>
            <ci_upper_limit>110.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration (Cmax) of Metformin</title>
        <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as single tablets.</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as single tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration (Cmax) of Metformin</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1680" spread="34.8"/>
                    <measurement group_id="O2" value="1780" spread="26.0"/>
                    <measurement group_id="O3" value="1220" spread="29.1"/>
                    <measurement group_id="O4" value="1190" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>94.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.4</ci_lower_limit>
            <ci_upper_limit>104.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>102.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.2</ci_lower_limit>
            <ci_upper_limit>113.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) for Linagliptin</title>
        <description>AUC0-infinity is based on predicted last concentration values.</description>
        <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as single tablets.</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as single tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) for Linagliptin</title>
          <description>AUC0-infinity is based on predicted last concentration values.</description>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471" spread="29.8"/>
                    <measurement group_id="O2" value="433" spread="22.2"/>
                    <measurement group_id="O3" value="483" spread="32.5"/>
                    <measurement group_id="O4" value="541" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>110.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.5</ci_lower_limit>
            <ci_upper_limit>120.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>89.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.2</ci_lower_limit>
            <ci_upper_limit>99.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-infinity) for Metformin</title>
        <description>AUC0-infinity is based on predicted last concentration values.</description>
        <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as single tablets.</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as single tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-infinity) for Metformin</title>
          <description>AUC0-infinity is based on predicted last concentration values.</description>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12200" spread="25.8"/>
                    <measurement group_id="O2" value="12500" spread="23.0"/>
                    <measurement group_id="O3" value="8440" spread="19.3"/>
                    <measurement group_id="O4" value="8210" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>98.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.0</ci_lower_limit>
            <ci_upper_limit>104.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>102.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.0</ci_lower_limit>
            <ci_upper_limit>109.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz for Linagliptin</title>
        <time_frame>1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as single tablets.</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as a fixed dose combination (FDC) tablet.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets</title>
            <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as single tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz for Linagliptin</title>
          <population>Treated Set</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248" spread="14.5"/>
                    <measurement group_id="O2" value="251" spread="15.3"/>
                    <measurement group_id="O3" value="266" spread="22.1"/>
                    <measurement group_id="O4" value="264" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>99.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.7</ci_lower_limit>
            <ci_upper_limit>104.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>100.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.1</ci_lower_limit>
            <ci_upper_limit>106.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First treatment with study drug until End-of-Study (which was 7 to 14 days after study drug treatment in Visit 3), i.e. 7 weeks plus 4 to 11 days after first treatment with study drug</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet</title>
          <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as a fixed dose combination (FDC) tablet.</description>
        </group>
        <group group_id="E2">
          <title>Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets</title>
          <description>Patients receiving 2.5 mg Linagliptin and 850 mg Metformin as single tablets.</description>
        </group>
        <group group_id="E3">
          <title>Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet</title>
          <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as a fixed dose combination (FDC) tablet.</description>
        </group>
        <group group_id="E4">
          <title>Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets</title>
          <description>Patients receiving 2.5 mg Linagliptin and 500 mg Metformin as single tablets.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

